<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3901">
  <stage>Registered</stage>
  <submitdate>25/03/2011</submitdate>
  <approvaldate>25/03/2011</approvaldate>
  <nctid>NCT01324479</nctid>
  <trial_identification>
    <studytitle>Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors</studytitle>
    <scientifictitle>A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2010-024101-12</secondaryid>
    <secondaryid>CINC280X2102</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Solid Tumors</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - INC280

Experimental: INC280 - 


Treatment: drugs: INC280


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence rate of dose-limiting toxicities and adverse events</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response by local investigator assessment</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must have evidence of c-MET dysregulation from either local data or the results of
             molecular pre-screening evaluations.

          -  Confirmed diagnosis of a solid tumor.

          -  Measureable lesion.

          -  Refractory to currently available treatment or no therapies available.

          -  18 years or older.

          -  ECOG performance status of 0, 1, or 2.

          -  Obtained written informed consent.

        Additional inclusion criteria for NSCLC patients EGFRwt with high c-MET expression:

          -  Written documentation of EGFRwt NSCLC.

          -  Written documentation of c-MET positivity.

          -  Patients should not have received more than three prior lines of antineoplastic
             therapy for NSCLC.

          -  Presence of at least one measurable lesion as determined by modified RECIST version
             1.1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>HCC with liver dysfunction greater than Child-Pugh A. Previous treatment with a c-MET
        inhibitor or HGF-targeting therapy. Symptomatic CNS metastases that are neurologically
        unstable or requiring increasing doses of steroids to control their CNS disease.

        Any CNS deficits. For patients with GBM, CNS symptoms grade 2 or greater. Subjects with
        significant or uncontrolled cardiovascular disease (eg, uncontrolled hypertension,
        peripheral vascular disease, congestive heart failure, cardiac arrhythmia, or acute
        coronary syndrome) within 6 months of starting study treatment or heart attack within 12
        months of starting study treatment.

        Receiving anti-epileptic drugs that are known to be strong inducers of CYP3A4. Prior or
        current anti-angiogenic therapy for patients with GBM. Radiation therapy within = 4 weeks
        (&lt; 12 for GBM) prior to the first dose of study drug or limited field radiotherapy within =
        2 weeks (&lt; 12 weeks GBM) prior to the start of study treatment. Any persistent side effect
        of prior radiotherapy must be resolved to = Grade 1 prior to the first dose of study drug.

        Additional exclusion criteria for NSCLC patients EGFRwt with high c-MET expression:

          -  Patients who have received more than three prior lines of antineoplastic therapies

          -  Any unresolved toxicity (CTCAE grade &gt; 1) from previous anti-cancer therapy or
             radiotherapy, except alopecia

          -  Patients have received anti-cancer therapies within the following time frames prior to
             the first dose of study treatment:

               -  Conventional cytotoxic chemotherapy: =4 weeks (=6 weeks for nitrosoureas and
                  mitomycin-C)

               -  Biologic therapy (e.g., antibodies): =4 weeks

               -  Non-cytotoxic small molecule therapeutics: =5 half-lives or =2 weeks (whichever
                  is longer)

               -  Other investigational agents: =4 weeks

               -  Radiation therapy (palliative setting is allowed.): =4 weeks

               -  Major surgery: =2 weeks

        Other protocol-defined inclusion/exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>29/02/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>131</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>4/07/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>Novartis Investigative Site - Westmead</hospital>
    <hospital>Novartis Investigative Site - Woolloongabba</hospital>
    <postcode>2145 - Westmead</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Tronche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>LILLE CÃ©dex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gottingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Oldenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kfar-Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>AN</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>FC</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>RE</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Korea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>the Netherlands</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Asturias</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Zaragoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taiwan ROC</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Songkla</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will assess the safety and efficacy of INC280 in patients with solid tumors that
      are refractory to current treatment or for which there is not a current standard of care and
      whose tumors have dysregulation of the c-MET pathway.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01324479</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>